Header Logo

STEPHEN GOTTSCHALK

TitleAdjunct Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address262 Danny Thomas Place
Memphis, TN 38105
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    T32CA272387     (GOTTSCHALK, STEPHEN)Sep 1, 2022 - Aug 31, 2027
    NIH
    T32 Training Program in Pediatric Immuno-Oncology and Immunotherapy
    Role: Principal Investigator
    R01NS106379     (BALYASNIKOVA, IRINA V ;GOTTSCHALK, STEPHEN)Sep 30, 2018 - Aug 31, 2023
    NIH
    Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy
    Role: Co-Principal Investigator
    R21NS089802     (BALYASNIKOVA, IRINA V)Sep 30, 2014 - Aug 31, 2017
    NIH
    IL13Ra2 targeted T-cell therapy for glioma
    Role: Co-Principal Investigator
    R01CA173750     (WUCHERPFENNIG, KAI W)Sep 13, 2012 - Jul 31, 2019
    NIH
    Reprogramming of T cells for the Treatment of Melanoma
    Role: Co-Principal Investigator
    R01CA148748     (SONG, XIAO-TONG)Sep 1, 2011 - Jul 31, 2016
    NIH
    Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Keller MD, Schattgen SA, Chandrakasan S, Allen EK, Jensen-Wachspress MA, Lazarski CA, Qayed M, Lang H, Hanley PJ, Tanna J, Pai SY, Parikh S, Berger SI, Gottschalk S, Pulsipher MA, Thomas PG, Bollard CM. Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication. Nat Commun. 2024 Mar 29; 15(1):2749. PMID: 38553461; PMCID: PMC10980733.
      Citations:    Fields:    Translation:HumansCells
    2. Petgrave Y, Selukar S, Epperly R, Naik S, Santos ND, Triplett BM, Gottschalk S, Bissler J, Talleur AC. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia. Pediatr Nephrol. 2024 Mar 20. PMID: 38507119.
      Citations:    Fields:    
    3. Kirk AM, Crawford JC, Chou CH, Guy C, Pandey K, Kozlik T, Shah RK, Chung S, Nguyen P, Zhang X, Wang J, Bell M, Mettelman RC, Allen EK, Pogorelyy MV, Kim H, Minervina AA, Awad W, Bajracharya R, White T, Long D, Gordon B, Morrison M, Glazer ES, Murphy AJ, Jiang Y, Fitzpatrick EA, Yarchoan M, Sethupathy P, Croft NP, Purcell AW, Federico SM, Stewart E, Gottschalk S, Zamora AE, DeRenzo C, Strome SE, Thomas PG. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T?cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell Rep Med. 2024 Mar 19; 5(3):101469. PMID: 38508137; PMCID: PMC10983114.
      Citations:    Fields:    Translation:HumansCells
    4. Epperly R, Li Y, Selukar S, Zeng E, Madden R, Mamcarz E, Naik S, Qudeimat A, Sharma A, Talleur A, Dallas MH, Gottschalk S, Srinivasan A, Triplett B, Epperly R, Li Y, Selukar S, Zeng E, Madden R, Mamcarz E, Naik S, Qudeimat A, Sharma A, Talleur A, Dallas MH, Gottschalk S, Srinivasan A, Triplett B. Disease Status and Interval between Hematopoietic Cell Transplantations Predict Outcome of Pediatric Patients Who Undergo Subsequent Transplantation for Relapsed Hematologic Malignancy. Transplant Cell Ther. 2024 Feb 20. PMID: 38387720.
      Citations:    Fields:    
    5. Zoine JT, Immadisetty K, Ibanez-Vega J, Moore SE, Nevitt C, Thanekar U, Tian L, Karouni A, Chockley PJ, Arthur B, Sheppard H, Klco JM, Langfitt DM, Krenciute G, Gottschalk S, Babu MM, Velasquez MP. Peptide-scFv antigen recognition domains effectively confer CAR T?cell multiantigen specificity. Cell Rep Med. 2024 Feb 20; 5(2):101422. PMID: 38350450; PMCID: PMC10897625.
      Citations:    Fields:    Translation:HumansCells
    6. Naik S, Gottschalk S. Is immune escape in the rearview mirror? Blood. 2024 Jan 11; 143(2):97-98. PMID: 38206641.
      Citations:    Fields:    Translation:Cells
    7. Pawlowski KD, Duffy JT, Gottschalk S, Balyasnikova IV. Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for Glioblastoma. Cancers (Basel). 2023 Dec 15; 15(24). PMID: 38136398; PMCID: PMC10741789.
      Citations:    
    8. Mai S, Hodges A, Chen HM, Zhang J, Wang YL, Liu Y, Nakatsu F, Wang X, Fang J, Xu Y, Davidov V, Kang K, Pingali SR, Ganguly S, Suzuki M, Konopleva M, Prinzing B, Zu Y, Gottschalk S, Lu Y, Chen SH, Pan PY. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy. Cancer Res. 2023 12 15; 83(24):4047-4062. PMID: 38098451.
      Citations:    Fields:    Translation:HumansCells
    9. Talleur AC, Naik S, Gottschalk S. Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):91-96. PMID: 38066941; PMCID: PMC10727085.
      Citations:    Fields:    Translation:HumansCells
    10. Haydar D, Iba?ez-Vega J, Crawford JC, Chou CH, Guy CS, Meehl M, Yi Z, Perry S, Laxton J, Cunningham T, Langfitt D, Vogel P, DeRenzo C, Gottschalk S, Roussel MF, Thomas PG, Krenciute G. CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity. Cancer Res Commun. 2023 12 01; 3(12):2430-2446. PMID: 37971169; PMCID: PMC10689147.
      Citations:    Translation:AnimalsCells
    11. Bell M, Lange S, Sejdiu BI, Ibanez J, Shi H, Sun X, Meng X, Nguyen P, Sutton M, Wagner J, Kc A, Langfitt D, Patil SL, Tan H, Pandey RV, Li Y, Yuan ZF, Anido AA, Ho M, Sheppard H, Vogel P, Yu J, Peng J, Chi H, Babu MM, Krenciute G, Gottschalk S. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling. Nat Biomed Eng. 2023 Nov 30. PMID: 38036617.
      Citations:    Fields:    
    12. Lareau CA, Yin Y, Maurer K, Sandor KD, Daniel B, Yagnik G, Pe?a J, Crawford JC, Spanjaart AM, Gutierrez JC, Haradhvala NJ, Riberdy JM, Abay T, Stickels RR, Verboon JM, Liu V, Buquicchio FA, Wang F, Southard J, Song R, Li W, Shrestha A, Parida L, Getz G, Maus MV, Li S, Moore A, Roberts ZJ, Ludwig LS, Talleur AC, Thomas PG, Dehghani H, Pertel T, Kundaje A, Gottschalk S, Roth TL, Kersten MJ, Wu CJ, Majzner RG, Satpathy AT. Latent human herpesvirus 6 is reactivated in CAR T cells. Nature. 2023 Nov; 623(7987):608-615. PMID: 37938768; PMCID: PMC10999258.
      Citations: 2     Fields:    Translation:HumansCells
    13. Epperly R, Shulkin BL, Bag AK, Cheng C, Inaba H, Lucas JT, Naik S, Triplett BM, Gottschalk S, Talleur AC. CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL. Blood Adv. 2023 10 24; 7(20):6320-6324. PMID: 37595052; PMCID: PMC10589782.
      Citations:    Fields:    Translation:HumansCells
    14. Ligon JA, Ramakrishna S, Ceppi F, Calkoen FG, Diorio C, Davis KL, Jacoby E, Gottschalk S, Schultz LM, Capitini CM, Ligon JA, Ramakrishna S, Calkoen FGJ, Diorio C, Davis KL, Gottschalk S, Schultz LM, Capitini CM. INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities. Transplant Cell Ther. 2024 Feb; 30(2):155-170. PMID: 37863355.
      Citations:    Fields:    Translation:HumansCells
    15. Yan KK, Condori J, Ma Z, Metais JY, Ju B, Ding L, Dhungana Y, Palmer LE, Langfitt DM, Ferrara F, Throm R, Shi H, Risch I, Bhatara S, Shaner B, Lockey TD, Talleur AC, Easton J, Meagher MM, Puck JM, Cowan MJ, Zhou S, Mamcarz E, Gottschalk S, Yu J. Integrome signatures of lentiviral gene therapy for SCID-X1 patients. Sci Adv. 2023 10 06; 9(40):eadg9959. PMID: 37801507; PMCID: PMC10558130.
      Citations:    Fields:    Translation:HumansCells
    16. Petgrave YP, Selukar S, Epperly R, Naik S, Santos ND, Triplett BM, Gottschalk S, Bissler J, Talleur AC. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia. Res Sq. 2023 Oct 06. PMID: 37886451; PMCID: PMC10602103.
      Citations:    
    17. Akel S, Poston L, Park JJ, Schoultz SB, Alloush L, Zheng F, Zhou S, Lockey T, Willis C, DeRenzo C, Gottschalk S. Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis. Cytotherapy. 2023 11; 25(11):1149-1154. PMID: 37676217; PMCID: PMC10916741.
      Citations:    Fields:    Translation:Cells
    18. Gottschalk S. Terrific cells for SARS-CoV-2. Haematologica. 2023 Jul 01; 108(7):1724-1725. PMID: 36475524; PMCID: PMC10316267.
      Citations:    Fields:    Translation:HumansCells
    19. Haydar D, Iba?ez-Vega J, Crawford JC, Chou CH, Guy C, Meehl M, Yi Z, Langfitt D, Vogel P, DeRenzo C, Gottschalk S, Roussel MF, Thomas PG, Krenciute G. CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity. Res Sq. 2023 Jun 06. PMID: 37333156; PMCID: PMC10275057.
      Citations:    
    20. Essawi K, Hakami W, Naeem Khan MB, Martin R, Zeng J, Chu R, Uchida N, Bonifacino AC, Krouse AE, Linde NS, Donahue RE, Blobel GA, Gerdemann U, Kean LS, Maitland SA, Wolfe SA, Metais JY, Gottschalk S, Bauer DE, Tisdale JF, Demirci S. Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation. Mol Ther Methods Clin Dev. 2023 Jun 08; 29:483-493. PMID: 37273902; PMCID: PMC10236215.
      Citations: 1     
    21. Vaidya A, Doherty E, Wu X, Huang S, Hebbar N, Thanekar U, Bonifant CL, Cheng C, Gottschalk S, Velasquez MP. Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation. Haematologica. 2023 04 01; 108(4):1039-1052. PMID: 35899386; PMCID: PMC10071120.
      Citations:    Fields:    
    22. Beckett AN, Chockley P, Pruett-Miller SM, Nguyen P, Vogel P, Sheppard H, Krenciute G, Gottschalk S, DeRenzo C. CD47 expression is critical for CAR T-cell survival in vivo. J Immunother Cancer. 2023 03; 11(3). PMID: 36918226; PMCID: PMC10016274.
      Citations:    Fields:    Translation:HumansCells
    23. Talleur AC, Gottschalk S. A tour de force provides novel insights into CD19-CAR T?cell resistance mechanisms. Cell Rep Med. 2023 02 21; 4(2):100949. PMID: 36812888; PMCID: PMC9975327.
      Citations: 1     Fields:    Translation:Cells
    24. Chockley PJ, Ibanez-Vega J, Krenciute G, Talbot LJ, Gottschalk S. Synapse-tuned CARs enhance immune cell anti-tumor activity. Nat Biotechnol. 2023 Oct; 41(10):1434-1445. PMID: 36732477; PMCID: PMC10394118.
      Citations:    Fields:    
    25. Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM, Lee-Chang C, Miska J, Lesniak MS, Gottschalk S, Balyasnikova IV. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer. 2023 02; 11(2). PMID: 36759014; PMCID: PMC9923337.
      Citations: 5     Fields:    Translation:AnimalsCells
    26. Lipsitt A, Beattie L, Harstead E, Li Y, Goorha S, Maron G, Gottschalk S, Triplett B, Naik S. Allogeneic CD34+ selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection. Pediatr Blood Cancer. 2023 03; 70(3):e30166. PMID: 36565276.
      Citations:    Fields:    Translation:HumansCells
    27. Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, Patil SL, Khanlari M, Inaba H, Klco JM, Mullighan CG, Krenciute G, Chockley PJ, Naik S, Langfitt DM, Mamonkin M, Obeng EA, Thomas PG, Gottschalk S, Velasquez MP. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022 12 22; 140(25):2684-2696. PMID: 35914226; PMCID: PMC9935551.
      Citations:    
    28. Pfeiffer T, Li Y, Ashcraft E, Karol SE, Rubnitz JE, Epperly R, Madden R, Mamcarz E, Obeng E, Qudeimat A, Sharma A, Srinivasan A, Suliman A, Talleur AC, Velasquez MP, Gottschalk S, Triplett BM, Naik S. Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML. Bone Marrow Transplant. 2023 03; 58(3):328-331. PMID: 36443431.
      Citations: 2     Fields:    Translation:Humans
    29. Talleur AC, Qudeimat A, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman A, Srinivasan A, Velasquez MP, Obeng EA, Willis C, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou SM, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood B, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S, M?tais JY. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Adv. 2022 11 08; 6(21):5737-5749. PMID: 35446934; PMCID: PMC9647829.
      Citations:    Fields:    
    30. Wilson TL, Kim H, Chou CH, Langfitt D, Mettelman RC, Minervina AA, Allen EK, Pogorelyy MV, Riberdy JM, Velasquez MP, Kottapalli P, Trivedi S, Olsen SR, Lockey T, Willis C, Meagher MM, Triplett BM, Talleur AC, Gottschalk S, Crawford JC, Thomas PG, M?tais JY. Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. Cancer Discov. 2022 09 02; 12(9):2098-2119. PMID: 35792801; PMCID: PMC9437573.
      Citations:    Fields:    
    31. Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Iba?ez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022 09; 609(7925):174-182. PMID: 36002574; PMCID: PMC9433322.
      Citations:    
    32. Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: 35325065; PMCID: PMC9346960.
      Citations:    Fields:    Translation:HumansCells
    33. Bell M, Gottschalk S. CAR T?cell therapy for solid tumors: Fatal attraction requires adhesion. Med (N Y). 2022 06 10; 3(6):353-354. PMID: 35690053.
      Citations:    Translation:HumansCells
    34. Zhang S, Black RG, Kohli K, Hayes BJ, Miller C, Koehne A, Schroeder BA, Abrams K, Schulte BC, Alexiev BA, Heimberger AB, Zhang A, Jing W, Ng JCK, Shinglot H, Seguin B, Salter AI, Riddell SR, Jensen MC, Gottschalk S, Moore PF, Torok-Storb B, Pollack SM. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. Mol Cancer Ther. 2022 06 01; 21(6):999-1009. PMID: 35405743.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    35. Mu-Mosley H, Ostermann L, Muftuoglu M, Vaidya A, Bonifant CL, Velasquez MP, Gottschalk S, Andreeff M. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models. Front Immunol. 2022; 13:880108. PMID: 35615350; PMCID: PMC9124830.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    36. Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PD. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711. PMID: 35134127; PMCID: PMC9053698.
      Citations: 1     Fields:    Translation:Humans
    37. Omer B, Cardenas MG, Pfeiffer T, Daum R, Huynh M, Sharma S, Nouraee N, Xie C, Tat C, Perconti S, Van Pelt S, Scherer L, DeRenzo C, Shum T, Gottschalk S, Arber C, Rooney CM. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022 04 01; 10(4):512-524. PMID: 35176142; PMCID: PMC8978620.
      Citations:    Fields:    Translation:AnimalsCells
    38. Maron GM, Hijano DR, Epperly R, Su Y, Tang L, Hayden RT, Naik S, Karol SE, Gottschalk S, Triplett BM, Talleur AC. Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. Front Oncol. 2022; 12:845540. PMID: 35356197; PMCID: PMC8959860.
      Citations: 1     
    39. Epperly R, Talleur AC, Li Y, Schell S, Tuggle M, Huang S, Pei D, Cheng C, Madden R, Mamcarz E, Naik S, Qudeimat A, Sharma A, Srinivasan A, Suliman A, Gottschalk S, Triplett BM, M?tais JY. Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients. Transplant Cell Ther. 2022 05; 28(5):262.e1-262.e10. PMID: 35151936; PMCID: PMC9081211.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    40. Hebbar N, Epperly R, Vaidya A, Thanekar U, Moore SE, Umeda M, Ma J, Patil SL, Langfitt D, Huang S, Cheng C, Klco JM, Gottschalk S, Velasquez MP. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nat Commun. 2022 01 31; 13(1):587. PMID: 35102167; PMCID: PMC8803836.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    41. Kim-Hoehamer YI, Riberdy JM, Zheng F, Park JJ, Shang N, Lockey T, Willis C, Akel S, Moore J, Meagher MM, Velasquez MP, Triplett BM, Talleur AC, Gottschalk S, Zhou S, M?tais JY. Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. Gene Ther. 2023 04; 30(3-4):222-231. PMID: 34997202; PMCID: PMC10286828.
      Citations:    Fields:    
    42. Ravich JW, Huang S, Zhou Y, Brown P, Pui CH, Inaba H, Cheng C, Gottschalk S, Triplett BM, Bonifant CL, Talleur AC. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. Transplant Cell Ther. 2022 02; 28(2):73.e1-73.e9. PMID: 34875402; PMCID: PMC8816862.
      Citations: 1     Fields:    Translation:Humans
    43. Zebley CC, Brown C, Mi T, Fan Y, Alli S, Boi S, Galletti G, Lugli E, Langfitt D, Metais JY, Lockey T, Meagher M, Triplett B, Talleur AC, Gottschalk S, Youngblood B. CD19-CAR T?cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Rep. 2021 11 30; 37(9):110079. PMID: 34852226; PMCID: PMC8800370.
      Citations: 5     Fields:    Translation:HumansCells
    44. Pearson AD, Mackall C, Shah NN, Reaman G, Ricafort R, Heenen D, Bassan A, Berntgen M, Bird N, Bleickardt E, Bouchkouj N, Bross P, Brownstein C, Cohen SB, de Rojas T, Ehrlich L, Fox E, Gottschalk S, Hanssens L, Hawkins DS, Horak ID, Taylor DH, Johnson C, Karres D, Ligas F, Ludwinski D, Mamonkin M, Marshall L, Masouleh BK, Matloub Y, Maude S, McDonough J, Norga K, Nysom K, Pappo A, Pearce L, Pieters R, Pule M, Richardson N, Scobie N, Sersch MA, Smith MA, Sterba J, Tasian SK, Weigel B, Weiner SL, Zwaan CM, Lesa G, Rossig C, Baruchel A, Minard-Colin V, Quint?s-Cardama A, Sch??ler-Lenz M, Vassal G. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 01; 160:112-133. PMID: 34840026.
      Citations: 1     Fields:    Translation:Humans
    45. Prinzing B, Zebley CC, Petersen CT, Fan Y, Anido AA, Yi Z, Nguyen P, Houke H, Bell M, Haydar D, Brown C, Boi SK, Alli S, Crawford JC, Riberdy JM, Park JJ, Zhou S, Velasquez MP, DeRenzo C, Lazzarotto CR, Tsai SQ, Vogel P, Pruett-Miller SM, Langfitt DM, Gottschalk S, Youngblood B, Krenciute G. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021 11 17; 13(620):eabh0272. PMID: 34788079; PMCID: PMC8733956.
      Citations: 7     Fields:    Translation:HumansCells
    46. Schreiner P, Velasquez MP, Gottschalk S, Zhang J, Fan Y. Unifying heterogeneous expression data to predict targets for CAR-T cell therapy. Oncoimmunology. 2021; 10(1):2000109. PMID: 34858726; PMCID: PMC8632331.
      Citations:    Fields:    Translation:HumansCells
    47. Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, Joubert J, Gottschalk S, Watanabe N, Leen A, Parihar R, Vera Valdes JF, Hoyos V. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11). PMID: 34815355; PMCID: PMC8611441.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    48. Wilson MH, Gottschalk S. Expect the unexpected: piggyBac and lymphoma. Blood. 2021 10 21; 138(16):1379-1380. PMID: 34673949.
      Citations:    Fields:    Translation:Animals
    49. Velasquez MP, Gottschalk S. Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer Toxicity. Blood Cancer Discov. 2021 Nov; 2(6):559-561. PMID: 35015677; PMCID: PMC9894579.
      Citations:    Fields:    
    50. Gottschalk S, Csapl?r M, Sz?llosi J, Vereb G, Sz?or ?. Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models. Cancers (Basel). 2021 Aug 26; 13(17). PMID: 34503109; PMCID: PMC8428348.
      Citations: 2     
    51. Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, Angenendt L, Schliemann C, Schmitt M, Gottschalk S, Rooney CM, M?ller-Tidow C. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021 07 29; 138(4):318-330. PMID: 34323938; PMCID: PMC8323977.
      Citations: 19     Fields:    Translation:HumansCells
    52. Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14. PMID: 34377737; PMCID: PMC8322039.
      Citations: 2     
    53. Hines MR, Keenan C, Maron Alfaro G, Cheng C, Zhou Y, Sharma A, Hurley C, Nichols KE, Gottschalk S, Triplett BM, Talleur AC. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021 08; 194(4):701-707. PMID: 34263927; PMCID: PMC8756350.
      Citations: 8     Fields:    Translation:Humans
    54. Delgoffe GM, Xu C, Mackall CL, Green MR, Gottschalk S, Speiser DE, Zehn D, Beavis PA. The role of exhaustion in CAR T cell therapy. Cancer Cell. 2021 07 12; 39(7):885-888. PMID: 34256903.
      Citations: 3     Fields:    Translation:HumansCells
    55. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2021 07 01; 131(13). PMID: 34196303; PMCID: PMC8245163.
      Citations: 2     Fields:    
    56. Talbot LJ, Chabot A, Funk A, Nguyen P, Wagner J, Ross A, Tillman H, Davidoff A, Gottschalk S, DeRenzo C. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells. Front Immunol. 2021; 12:691741. PMID: 34211478; PMCID: PMC8239305.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    57. Chockley P, Patil SL, Gottschalk S. Transient blockade of TBK1/IKKe allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors. Cytotherapy. 2021 09; 23(9):787-792. PMID: 34119434; PMCID: PMC8425283.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    58. Bell M, Gottschalk S. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Front Immunol. 2021; 12:684642. PMID: 34177932; PMCID: PMC8220823.
      Citations: 4     Fields:    Translation:HumansAnimals
    59. Haydar D, Houke H, Chiang J, Yi Z, Caldwell K, Zhu X, Mercer KS, Stripay JL, Shaw TI, Vogel P, DeRenzo C, Baker SJ, Roussel MF, Gottschalk S, Krenciute G, Od? Z. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol. 2021 06 01; 23(6):999-1011. PMID: 33320196; PMCID: PMC8168826.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    60. Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill L, Randhawa J, Gottschalk S, Krance R, Wang T, Wu M, Robertson C, Gee AP, Chung B, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597. PMID: 33270816; PMCID: PMC8120140.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    61. Ferrari F, Salviato E, Brenner MK, Gottschalk S, Hoyos V, Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Locatelli F, Caruana I, Del Bufalo F. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5). PMID: 33963009; PMCID: PMC8108682.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    62. Sharma A, Li Y, Huang S, Talleur AC, Suliman A, Qudeimat A, Srinivasan A, Mamcarz E, Madden R, Cheng C, Gottschalk S, Triplett BM. Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS. Bone Marrow Transplant. 2021 08; 56(8):1866-1875. PMID: 33742153.
      Citations: 2     Fields:    Translation:Humans
    63. Lange S, Sand LGL, Bell M, Patil SL, Langfitt D, Gottschalk S. A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function. Cancer Discov. 2021 07; 11(7):1661-1671. PMID: 33563660; PMCID: PMC8292158.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    64. Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR Cell Therapy-More Than a Pipe Dream. Front Immunol. 2020; 11:618427. PMID: 33488631; PMCID: PMC7821739.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    65. Wagner J, Wickman E, Shaw TI, Anido AA, Langfitt D, Zhang J, Porter SN, Pruett-Miller SM, Tillman H, Krenciute G, Gottschalk S. Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin. Cancer Immunol Res. 2021 03; 9(3):279-290. PMID: 33355188; PMCID: PMC7925432.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    66. Prinzing B, Schreiner P, Bell M, Fan Y, Krenciute G, Gottschalk S. MyD88/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight. 2020 11 05; 5(21). PMID: 33148882; PMCID: PMC7710311.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    67. Maron G, Kaste S, Bahrami A, Neel M, Malech HL, Puck JM, Cowan MJ, Gottschalk S, Mamcarz E. Successful SCID gene therapy in infant with disseminated BCG. J Allergy Clin Immunol Pract. 2021 02; 9(2):993-995.e1. PMID: 32949809; PMCID: PMC7870513.
      Citations:    Fields:    Translation:HumansCells
    68. Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? Mol Ther. 2020 11 04; 28(11):2320-2339. PMID: 32979309; PMCID: PMC7647674.
      Citations: 53     Fields:    Translation:HumansCells
    69. Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 2021 04; 28(3-4):321-334. PMID: 32873870; PMCID: PMC8057949.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    70. Chapman NM, Gottschalk S, Chi H. Preventing Ubiquitination Improves CAR T Cell Therapy via 'CAR Merry-Go-Around'. Immunity. 2020 08 18; 53(2):243-245. PMID: 32814023.
      Citations: 2     Fields:    Translation:Cells
    71. Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549. PMID: 32669548; PMCID: PMC7363864.
      Citations: 33     Fields:    Translation:HumansCells
    72. Cao F, Nguyen P, Hong B, DeRenzo C, Rainusso NC, Rodriguez Cruz T, Wu MF, Liu H, Song XT, Suzuki M, Wang LL, Yustein JT, Gottschalk S. Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells. Adv Cell Gene Ther. 2021 Apr; 4(2). PMID: 33829146; PMCID: PMC8021125.
      Citations: 2     
    73. Zebley CC, Gottschalk S, Youngblood B. Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. Trends Immunol. 2020 08; 41(8):665-675. PMID: 32624330; PMCID: PMC7395868.
      Citations: 21     Fields:    Translation:Cells
    74. Riberdy JM, Zhou S, Zheng F, Kim YI, Moore J, Vaidya A, Throm RE, Sykes A, Sahr N, Bonifant CL, Ryu B, Gottschalk S, Velasquez MP. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing. Mol Ther Methods Clin Dev. 2020 Sep 11; 18:571-581. PMID: 32775492; PMCID: PMC7393323.
      Citations: 5     
    75. Nguyen P, Okeke E, Clay M, Haydar D, Justice J, O'Reilly C, Pruett-Miller S, Papizan J, Moore J, Zhou S, Throm R, Krenciute G, Gottschalk S, DeRenzo C. Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28? T Cells. Mol Ther Oncolytics. 2020 Sep 25; 18:202-214. PMID: 32728609; PMCID: PMC7369352.
      Citations: 12     
    76. Epperly R, Gottschalk S, Velasquez MP. A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy. Front Oncol. 2020; 10:262. PMID: 32185132; PMCID: PMC7058784.
      Citations: 26     
    77. Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK, Suzuki M. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262. PMID: 32145203; PMCID: PMC7210703.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    78. Epperly R, Gottschalk S, Velasquez MP. Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. Children (Basel). 2020 Feb 17; 7(2). PMID: 32079207; PMCID: PMC7072334.
      Citations: 6     
    79. Naik S, Vasileiou S, Aguayo-Hiraldo P, Mukhi S, Sasa G, Martinez C, Krance RA, Gottschalk S, Leen A. Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant. 2020 05; 26(5):911-919. PMID: 31927102.
      Citations: 2     Fields:    Translation:HumansCells
    80. DeRenzo C, Gottschalk S. Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. Adv Exp Med Biol. 2020; 1257:109-131. PMID: 32483735; PMCID: PMC7385999.
      Citations: 3     Fields:    Translation:HumansCells
    81. Mamcarz E, Madden R, Qudeimat A, Srinivasan A, Talleur A, Sharma A, Suliman A, Maron G, Sunkara A, Kang G, Leung W, Gottschalk S, Triplett BM. Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplant. 2020 05; 55(5):929-938. PMID: 31740766; PMCID: PMC7202974.
      Citations: 11     Fields:    Translation:HumansCells
    82. Naik S, Martinez CA, Omer B, Sasa G, Yassine K, Allen CE, Kamdar K, Orth R, Wu M, Leung K, Gottschalk S, Brenner MK, Heslop HE, Krance RA. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695. PMID: 31511228; PMCID: PMC6759733.
      Citations: 2     Fields:    Translation:Humans
    83. Tzannou I, Watanabe A, Naik S, Daum R, Kuvalekar M, Leung KS, Martinez C, Sasa G, Wu M, Gee AP, Krance RA, Gottschalk S, Heslop HE, Omer B. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019 09 10; 3(17):2571-2580. PMID: 31481503; PMCID: PMC6737421.
      Citations: 12     Fields:    Translation:HumansCells
    84. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2019 Jul 02; 129(8):3464. PMID: 31264975; PMCID: PMC6668664.
      Citations: 10     Fields:    
    85. Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, Tang X, Janssen W, Ryu BY, De Ravin SS, Weiss MJ, Youngblood B, Long-Boyle JR, Gottschalk S, Meagher MM, Malech HL, Puck JM, Cowan MJ, Sorrentino BP. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med. 2019 04 18; 380(16):1525-1534. PMID: 30995372; PMCID: PMC6636624.
      Citations: 72     Fields:    Translation:HumansCellsCTClinical Trials
    86. Mata M, Gottschalk S. Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T?Cell Therapy for Solid Tumors. Drugs. 2019 Mar; 79(4):401-415. PMID: 30796733; PMCID: PMC6613829.
      Citations: 12     Fields:    Translation:HumansCells
    87. Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci Rep. 2019 02 22; 9(1):2636. PMID: 30796310; PMCID: PMC6385254.
      Citations: 16     Fields:    Translation:HumansCells
    88. DeRenzo C, Gottschalk S. Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors. Front Immunol. 2019; 10:218. PMID: 30828333; PMCID: PMC6384227.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    89. Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375. PMID: 30651290; PMCID: PMC7906796.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    90. Omer B, Castillo PA, Tashiro H, Shum T, Huynh MTA, Cardenas M, Tanaka M, Lewis A, Sauer T, Parihar R, Lapteva N, Schmueck-Henneresse M, Mukherjee M, Gottschalk S, Rooney CM. Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Front Med (Lausanne). 2018; 5:343. PMID: 30619856; PMCID: PMC6297364.
      Citations: 3     
    91. Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223. PMID: 30396848; PMCID: PMC6435433.
      Citations: 10     Fields:    Translation:HumansCells
    92. DeRenzo C, Lam C, Rodriguez-Galindo C, Rapkin L, Gottschalk S, Venkatramani R. Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. Pediatr Blood Cancer. 2019 01; 66(1):e27469. PMID: 30318742; PMCID: PMC6249063.
      Citations: 1     Fields:    Translation:Humans
    93. McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361. PMID: 30262660; PMCID: PMC6265652.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    94. Krebs S, Ahad A, Carter LM, Eyquem J, Brand C, Bell M, Ponomarev V, Reiner T, Meares CF, Gottschalk S, Sadelain M, Larson SM, Weber WA. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. J Nucl Med. 2018 12; 59(12):1894-1900. PMID: 29903928; PMCID: PMC6278895.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    95. DeRenzo C, Krenciute G, Gottschalk S. The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:830-837. PMID: 30231350.
      Citations: 10     Fields:    Translation:HumansCells
    96. Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, Nicholas S, Chinn I, Orange JS, Rider NL, Leung KS, Naik S, Carrum G, Sasa G, Hegde M, Omer BA, Ahmed N, Allen CE, Khaled Y, Wu MF, Liu H, Gottschalk SM, Heslop HE, Brenner MK, Krance RA, Martinez CA. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650. PMID: 29630926.
      Citations: 8     Fields:    Translation:Humans
    97. Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, Legras X, Bissig-Choisat B, Garaigorta U, Gottschalk S, Bissig KD. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 2018 05; 20(5):697-705. PMID: 29631939; PMCID: PMC6038120.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    98. Prinzing BL, Gottschalk SM, Krenciute G. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? Expert Rev Anticancer Ther. 2018 05; 18(5):451-461. PMID: 29533108; PMCID: PMC6191291.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    99. Yanir AD, Martinez CA, Sasa G, Leung K, Gottschalk S, Omer B, Ahmed N, Hegde M, Eunji J, Liu H, Heslop HE, Brenner MK, Krance RA, Naik S. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431. PMID: 29550628.
      Citations: 8     Fields:    Translation:Humans
    100. Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, Balyasnikova IV. Adoptive Transfer of IL13Ra2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Mol Ther. 2018 04 04; 26(4):986-995. PMID: 29503195; PMCID: PMC6079480.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    101. Yi Z, Prinzing BL, Cao F, Gottschalk S, Krenciute G. Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma. Mol Ther Methods Clin Dev. 2018 Jun 15; 9:70-80. PMID: 29552579; PMCID: PMC5852415.
      Citations: 43     
    102. Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139. PMID: 29315015; PMCID: PMC5891126.
      Citations: 75     Fields:    Translation:HumansCells
    103. Ngwube A, Hanson IC, Orange J, Rider NL, Seeborg F, Shearer W, Noroski L, Nicholas S, Forbes L, Leung K, Sasa G, Naik S, Hegde M, Omer B, Ahmed N, Allen C, Gottschalk S, Wu MF, Liu H, Brenner M, Heslop H, Krance R, Martinez C. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541. PMID: 29196075.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    104. Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2018 01 04; 131(1):30-38. PMID: 29118005; PMCID: PMC5755042.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    105. Bonifant CL, Velasquez MP, Gottschalk S. Advances in immunotherapy for pediatric acute myeloid leukemia. Expert Opin Biol Ther. 2018 01; 18(1):51-63. PMID: 28945115.
      Citations: 8     Fields:    Translation:HumansCells
    106. Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, Suzuki M. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451. PMID: 28974431; PMCID: PMC5675597.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    107. Allen U, Boyer O, Bucuvalas J, Colledan M, Cuturi MC, d'Antiga L, Debray D, Dezsofi A, Goyet JV, Dhawan A, Durmaz O, Falk C, Feng S, Frauca E, Ganschow R, Gottschalk S, Hadzic N, Hierro L, Horslen S, Hubscher S, Karam V, Kelly D, Maecker-Kolhoff B, Mazariegos G, McKiernan P, Melk A, Nobili V, Reding R, Sciveres M, Sharif K, Socha P, Toso C, Vajro P, Verma A, Wildhaber BE, Baumann U, McLin VA, Fischler B, Franchi-Abella S, Ozgen? F. Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation: Summary of an ESPGHAN Monothematic Conference. J Pediatr Gastroenterol Nutr. 2017 09; 65(3):e53-e59. PMID: 28319600.
      Citations: 4     Fields:    Translation:Humans
    108. Kruse RL, Shum T, Legras X, Barzi M, Pankowicz FP, Gottschalk S, Bissig KD. In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy. Mol Ther Methods Clin Dev. 2017 Dec 15; 7:32-41. PMID: 29018834; PMCID: PMC5626922.
      Citations: 5     
    109. Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247. PMID: 28830878; PMCID: PMC5669830.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    110. Velasquez MP, Szoor A, Vaidya A, Thakkar A, Nguyen P, Wu MF, Liu H, Gottschalk S. CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells. Cancer Immunol Res. 2017 10; 5(10):860-870. PMID: 28821531; PMCID: PMC5626647.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    111. Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discov. 2017 11; 7(11):1306-1319. PMID: 28801306; PMCID: PMC5780189.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    112. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557. PMID: 28783452; PMCID: PMC5662844.
      Citations: 135     Fields:    Translation:HumansCellsCTClinical Trials
    113. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101. PMID: 28426845; PMCID: PMC5747970.
      Citations: 269     Fields:    Translation:HumansCellsCTClinical Trials
    114. Szoor A, Vaidya A, Velasquez MP, Mei Z, Galvan DL, Torres D, Gee A, Heczey A, Gottschalk S. T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics. 2017 Sep 15; 6:69-79. PMID: 28856237; PMCID: PMC5562179.
      Citations: 10     
    115. Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213. PMID: 28676343; PMCID: PMC5589064.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    116. Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV, Gottschalk S. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Ra2-CAR T Cells but Results in Antigen Loss Variants. Cancer Immunol Res. 2017 07; 5(7):571-581. PMID: 28550091; PMCID: PMC5746871.
      Citations: 124     Fields:    Translation:HumansAnimalsCells
    117. Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, Suzuki M. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051. PMID: 28235763; PMCID: PMC5392365.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    118. Velasquez MP, Gottschalk S. Targeting CD19: the good, the bad, and CD81. Blood. 2017 01 05; 129(1):9-10. PMID: 28057672; PMCID: PMC5216268.
      Citations: 4     Fields:    
    119. McLaughlin LP, Gottschalk S, Rooney CM, Bollard CM. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods Mol Biol. 2017; 1532:255-265. PMID: 27873282.
      Citations: 11     Fields:    Translation:HumansCells
    120. Mata M, Gottschalk S. Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers. Mol Ther. 2016 09; 24(9):1511-2. PMID: 27687136; PMCID: PMC5113118.
      Citations: 2     Fields:    Translation:HumansAnimals
    121. Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2017 05; 28(5):437-448. PMID: 27530312; PMCID: PMC5444493.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    122. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52. PMID: 27427982; PMCID: PMC4966331.
      Citations: 249     Fields:    Translation:HumansAnimalsCells
    123. Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther. 2016 09 29; 24(9):1615-26. PMID: 27401038; PMCID: PMC5113097.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    124. Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriguez-Cruz T, Szoor A, Bonifant CL, Gerken C, Cooper LJ, Song XT, Gottschalk S. T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Sci Rep. 2016 06 03; 6:27130. PMID: 27255991; PMCID: PMC4891739.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    125. DeRenzo C, Gottschalk S. Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update. J Clin Cell Immunol. 2016 Apr; 7(2). PMID: 27313973; PMCID: PMC4904842.
      Citations:    
    126. Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Ra2-positive Glioma. Mol Ther. 2016 Feb; 24(2):354-363. PMID: 26514825; PMCID: PMC4817815.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    127. Wakefield A, Pignata A, Ghazi A, Ashoori A, Hegde M, Landi D, Gray T, Scheurer ME, Chintagumpala M, Adesina A, Gottschalk S, Hicks J, Powell SZ, Ahmed N. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 2015 Nov; 125(2):307-15. PMID: 26341370; PMCID: PMC4612329.
      Citations: 11     Fields:    Translation:HumansCells
    128. Iwahori K, Song XT, Gottschalk S. Response to "in vivo secretion of anti-CD3 ? anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement". Mol Ther. 2015 Apr; 23(4):613. PMID: 25849424; PMCID: PMC4395792.
      Citations:    Fields:    Translation:HumansAnimalsCells
    129. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96. PMID: 25800760; PMCID: PMC4429176.
      Citations: 373     Fields:    Translation:HumansCellsCTClinical Trials
    130. Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, Gottschalk S, Brenner M, Heslop H, Krance R. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72. PMID: 25765555.
      Citations: 10     Fields:    Translation:Humans
    131. Gottschalk S, Rooney CM. Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol. 2015; 391:427-54. PMID: 26428384; PMCID: PMC4655436.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    132. Mata M, Gottschalk S. Adoptive cell therapy for sarcoma. Immunotherapy. 2015; 7(1):21-35. PMID: 25572477; PMCID: PMC4331182.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    133. Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S, Mata M. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 2014 Oct; 37(8):407-15. PMID: 25198528; PMCID: PMC4163948.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    134. Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, Powell D, Ribas A, Rosenberg S, Sadelain M, Till B, Patterson AP, Jambou RC, Rosenthal E, Gargiulo L, Montgomery M, Kohn DB. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74. PMID: 25186558; PMCID: PMC4435492.
      Citations: 30     Fields:    Translation:HumansCells
    135. Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song XT, Gottschalk S. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther. 2015 Jan; 23(1):171-8. PMID: 25142939; PMCID: PMC4426792.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    136. Krebs S, Gottschalk S. Cell carriers to attack glioma. Cytotherapy. 2014 Jul; 16(7):871-2. PMID: 24910384.
      Citations:    Fields:    Translation:HumansAnimalsCells
    137. Krebs S, Chow KK, Yi Z, Rodriguez-Cruz T, Hegde M, Gerken C, Ahmed N, Gottschalk S. T cells redirected to interleukin-13Ra2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ra1. Cytotherapy. 2014 Aug; 16(8):1121-31. PMID: 24841514; PMCID: PMC4087074.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    138. Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM, Ngo MC. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203. PMID: 24714353; PMCID: PMC4133102.
      Citations: 28     Fields:    Translation:HumansCells
    139. Gottschalk S, Kakarla S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014 Mar-Apr; 20(2):151-5. PMID: 24667962; PMCID: PMC4050065.
      Citations: 80     Fields:    Translation:Humans
    140. Gottschalk S, Rooney CM. Harnessing the immune system to potentiate oncolytics. Mol Ther. 2014 Feb; 22(2):239-240. PMID: 24487560; PMCID: PMC3916053.
      Citations:    Fields:    Translation:HumansCells
    141. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan; 257(1):107-26. PMID: 24329793; PMCID: PMC3874724.
      Citations: 230     Fields:    Translation:HumansAnimalsCells
    142. DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol. 2014; 804:323-40. PMID: 24924183; PMCID: PMC4617538.
      Citations: 6     Fields:    Translation:HumansCells
    143. Krebs S, Derenzo C, Gottschalk S, Rodr?guez-Cruz TG. Genetically modified T cells to target glioblastoma. Front Oncol. 2013 Dec 31; 3:322. PMID: 24427741; PMCID: PMC3876295.
      Citations: 12     
    144. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808. PMID: 24344220; PMCID: PMC3940538.
      Citations: 208     Fields:    Translation:HumansCellsCTClinical Trials
    145. Gottschalk S, Yu F, Ji M, Kakarla S, Song XT. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One. 2013; 8(12):e82658. PMID: 24349329; PMCID: PMC3861387.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    146. Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res. 2015 Mar; 32(3):779-92. PMID: 24203492; PMCID: PMC4014531.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    147. Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kan R, Lim WT, Tan SH, Ong WS, Cheung YB, Tan EH, Connolly JE, Gottschalk S, Toh HC. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 2014 Jan; 22(1):132-9. PMID: 24297049; PMCID: PMC3978790.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    148. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014 Jan; 22(1):102-11. PMID: 24135899; PMCID: PMC3978793.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    149. Brenner MK, Gottschalk S, Leen AM, Vera JF. Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct; 14(11):e447-e456. PMID: 24079872; PMCID: PMC3916772.
      Citations: 15     Fields:    Translation:HumansAnimals
    150. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Gottachalk S, Yvon E, Ahmed N. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101. PMID: 23939024; PMCID: PMC3831041.
      Citations: 163     Fields:    Translation:HumansAnimalsCells
    151. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N, Sch?nfeld K. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013 Jul 09; 2:e105. PMID: 23839099; PMCID: PMC3731887.
      Citations: 200     
    152. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21. PMID: 23783429; PMCID: PMC3831033.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    153. Brehm C, Huenecke S, Pfirrmann V, Rossig C, Mackall CL, Bollard CM, Gottschalk S, Schlegel PG, Klingebiel T, Bader P. Highlights of the third International Conference on Immunotherapy in Pediatric Oncology. Pediatr Hematol Oncol. 2013 Aug; 30(5):349-66. PMID: 23758210.
      Citations:    Fields:    Translation:Humans
    154. Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013 Aug; 21(8):1611-20. PMID: 23732988; PMCID: PMC3734659.
      Citations: 118     Fields:    Translation:HumansAnimalsCells
    155. Kalra M, Gottschalk S. Targeting EBV's Achilles' heel with antigen-specific T cells. Immunotherapy. 2013 Apr; 5(4):353-5. PMID: 23557418; PMCID: PMC3723807.
      Citations:    Fields:    
    156. Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18. PMID: 23152545; PMCID: PMC3709638.
      Citations: 41     Fields:    Translation:HumansCells
    157. Kakarla S, Song XT, Gottschalk S. Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy. 2012 Nov; 4(11):1129-38. PMID: 23194363; PMCID: PMC3568630.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    158. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu MF, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ahmed N, Gottschalk S. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013 Mar; 21(3):629-37. PMID: 23070117; PMCID: PMC3589173.
      Citations: 124     Fields:    Translation:HumansAnimalsCells
    159. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32. PMID: 22801446; PMCID: PMC3412490.
      Citations: 107     Fields:    Translation:HumansCells
    160. Gottschalk S. Interleukin-13 receptor a2: glioma's unlucky receptor? Cytotherapy. 2012 Jul; 14(6):645-6. PMID: 22616783.
      Citations:    Fields:    Translation:HumansCells
    161. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68. PMID: 22306904; PMCID: PMC3280423.
      Citations: 35     Fields:    Translation:HumansCells
    162. Shaffer DR, Sheehan AM, Yi Z, Rodgers CC, Bollard CM, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61. PMID: 21994111; PMCID: PMC3258475.
      Citations: 1     Fields:    Translation:HumansCells
    163. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68. PMID: 21915103; PMCID: PMC3242656.
      Citations: 39     Fields:    Translation:HumansCells
    164. Capitini CM, Gottschalk S, Brenner M, Cooper LJ, Handgretinger R, Mackall CL. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep; 28(6):459-60. PMID: 21854215.
      Citations: 2     Fields:    Translation:Humans
    165. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43. PMID: 21772253; PMCID: PMC3242651.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    166. Salsman VS, Chow KK, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One. 2011; 6(5):e20267. PMID: 21647415; PMCID: PMC3103535.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    167. Gottschalk S. TILling head and neck cancer for cell therapy. Cytotherapy. 2011 Aug; 13(7):772-3. PMID: 21539499.
      Citations:    Fields:    Translation:HumansCells
    168. Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86. PMID: 21539497; PMCID: PMC3692015.
      Citations: 24     Fields:    Translation:HumansCells
    169. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49. PMID: 21454450; PMCID: PMC3112034.
      Citations: 100     Fields:    Translation:HumansCells
    170. Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011 May; 13(5):518-22. PMID: 21361747; PMCID: PMC3186062.
      Citations: 13     Fields:    Translation:HumansCells
    171. Chow KH, Gottschalk S. Cellular immunotherapy for high-grade glioma. Immunotherapy. 2011 Mar; 3(3):423-34. PMID: 21395383; PMCID: PMC3130624.
      Citations: 14     Fields:    Translation:HumansCells
    172. Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011 Apr 21; 117(16):4304-14. PMID: 21304103; PMCID: PMC3087480.
      Citations: 84     Fields:    Translation:HumansAnimalsCells
    173. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90. PMID: 20948438; PMCID: PMC2964409.
      Citations: 86     Fields:    Translation:HumansCellsCTClinical Trials
    174. Song XT, Turnis ME, Zhou X, Zhu W, Hong BX, Rollins L, Rabinovich B, Chen SY, Rooney CM, Gottschalk S. A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther. 2011 Jan; 19(1):211-7. PMID: 20959814; PMCID: PMC3017450.
      Citations: 13     Fields:    Translation:AnimalsCells
    175. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9. PMID: 20429793; PMCID: PMC2914831.
      Citations: 34     Fields:    Translation:Cells
    176. Turnis ME, Song XT, Bear A, Foster AE, Gottschalk S, Brenner MK, Chen SY, Rooney CM. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32. PMID: 20817880; PMCID: PMC3153346.
      Citations: 18     Fields:    Translation:AnimalsCells
    177. Shaffer DR, Rooney CM, Gottschalk S. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy. 2010 Sep; 2(5):663-71. PMID: 20874650; PMCID: PMC3075565.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    178. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010 Apr; 21(4):427-37. PMID: 19905893; PMCID: PMC2938363.
      Citations: 74     Fields:    Translation:HumansCells
    179. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Gottschalk SM, Bollard CM, Heslop HE, Brenner MK, Krance RA. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81. PMID: 20348004; PMCID: PMC2919628.
      Citations: 18     Fields:    Translation:Humans
    180. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15; 16(2):474-85. PMID: 20068073; PMCID: PMC3682507.
      Citations: 174     Fields:    Translation:HumansAnimalsCells
    181. Gao X, Xue Z, Xing J, Lee DY, Gottschalk SM, Heslop HE, Bollard CM, Wong ST. Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. Acad Radiol. 2010 Apr; 17(4):479-88. PMID: 20060747; PMCID: PMC2846835.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    182. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87. PMID: 19532139; PMCID: PMC2835000.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    183. Ahmed N, Gottschalk S. How to design effective vaccines: lessons from an old success story. Expert Rev Vaccines. 2009 May; 8(5):543-6. PMID: 19397411; PMCID: PMC3140531.
      Citations: 8     Fields:    Translation:HumansCells
    184. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52. PMID: 18940679.
      Citations: 26     Fields:    Translation:HumansCells
    185. Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304. PMID: 18940685.
      Citations: 7     Fields:    Translation:Humans
    186. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50. PMID: 18971421; PMCID: PMC2656271.
      Citations: 58     Fields:    Translation:HumansCellsCTClinical Trials
    187. Gottschalk S. Clinical and virological characteristics of patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation: insights and questions. Clin Infect Dis. 2008 May 15; 46(10):1535-6. PMID: 18419487.
      Citations: 1     Fields:    Translation:Humans
    188. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45. PMID: 17609424; PMCID: PMC2018666.
      Citations: 157     Fields:    Translation:HumansCellsCTClinical Trials
    189. Louis CU, Paulino AC, Gottschalk S, Bertuch AA, Chintagumpala M, Heslop HE, Russell HV. A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5. PMID: 17609631.
      Citations: 7     Fields:    Translation:Humans
    190. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64. PMID: 17575166.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    191. Seiler MP, Gottschalk S, Cerullo V, Ratnayake M, Mane VP, Clarke C, Palmer DJ, Ng P, Rooney CM, Lee B. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther. 2007 Feb; 15(2):386-92. PMID: 17235318.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    192. Leen A, Ratnayake M, Foster A, Heym K, Ahmed N, Rooney CM, Gottschalk S. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107. PMID: 17198088.
      Citations: 15     Fields:    Translation:HumansCells
    193. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84. PMID: 17162209.
      Citations: 29     Fields:    Translation:HumansCells
    194. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9. PMID: 16835376; PMCID: PMC1895521.
      Citations: 84     Fields:    Translation:HumansCells
    195. Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42. PMID: 16753867.
      Citations: 11     Fields:    Translation:HumansCells
    196. Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7. PMID: 16507214.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    197. Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82. PMID: 17824182.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    198. Pacheco SE, Gottschalk SM, Gresik MV, Dishop MK, Okmaura T, McCormick TG. Chronic active Epstein-Barr virus infection of natural killer cells presenting as severe skin reaction to mosquito bites. J Allergy Clin Immunol. 2005 Aug; 116(2):470-2. PMID: 16083813.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    199. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56:29-44. PMID: 15660500.
      Citations: 132     Fields:    Translation:HumansCells
    200. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005 Jan; 46(1):1-10. PMID: 15621775.
      Citations: 43     Fields:    Translation:Humans
    201. Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood. 2005 Mar 15; 105(6):2436-42. PMID: 15536147.
      Citations: 21     Fields:    Translation:HumansCells
    202. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27. PMID: 15235393.
      Citations: 35     Fields:    Translation:HumansCells
    203. Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56. PMID: 12806278.
      Citations: 23     Fields:    Translation:HumansCells
    204. Gottschalk S, Heslop HE, Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002; 84:175-201. PMID: 11883527.
      Citations: 6     Fields:    Translation:HumansCells
    205. Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42. PMID: 12611071.
      Citations: 8     Fields:    Translation:HumansCells
    206. Waheed A, Schmidt B, Laidler P, von Figura K, Gottschalk S. Sequential processing of lysosomal acid phosphatase by a cytoplasmic thiol proteinase and a lysosomal aspartyl proteinase. EMBO J. 1989 Nov; 8(11):3215-9. PMID: 2684640; PMCID: PMC401441.
      Citations: 20     Fields:    Translation:HumansCells
    207. Waheed A, von Figura K, Gottschalk S. Targeting of lysosomal acid phosphatase with altered carbohydrate. Biol Chem Hoppe Seyler. 1989 Jan; 370(1):75-80. PMID: 2540767.
      Citations: 5     Fields:    Translation:Cells
    GOTTSCHALK's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (528)
    Explore
    _
    Co-Authors (85)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _